×
About 2,984 results

ALLMedicine™ Bladder Dysfunction Center

Research & Reviews  1,465 results

ACTG2 Visceral Myopathy - GeneReviews® - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/n/gene/actg2-dis/

May 5th, 2021 - ACTG2 visceral myopathy is a disorder of smooth muscle dysfunction of the bladder and gastrointestinal system with phenotypic spectrum that ranges from mild to severe. Bladder involvement can range from neonatal megacystis and megaureter (with its...

Is coronavirus disease 2019 associated with indicators of long-term bladder dysfunction?
https://doi.org/10.1002/nau.24682
Neurourology and Urodynamics; Welk B, Richard L et. al.

May 4th, 2021 - Early reports have suggested that coronavirus disease 2019 (COVID-19) can present with significant urinary frequency and nocturia, and that these symptoms correlate with markers of inflammation in the urine. We evaluated surrogate markers of chron...

Physical activity effects on bladder dysfunction in an obese and insulin-resistant muri...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077148
Physiological Reports; de Oliveira AM, Fonseca FMF et. al.

Apr 27th, 2021 - To investigate the role of physical activity in functional and molecular bladder alterations in an obese and insulin-resistant murine model. Wistar rats were randomized into 1. physical activity and standard diet; 2. physical activity and high-fat...

Suspected cauda equina syndrome: no reduction in investigation, referral and treatment ...
https://doi.org/10.1308/rcsann.2021.0011
Annals of the Royal College of Surgeons of England; Woodfield J, Brennan PM et. al.

Mar 8th, 2021 - Compression of the cauda equina can lead to bladder, bowel and sexual dysfunction with lower limb pain, numbness and weakness. Urgent surgical decompression aims to prevent progressive neurological deficit. Symptoms of cauda equina syndrome (CES),...

Efficacy of the combination of KPR-5714, a novel transient receptor potential melastati...
https://doi.org/10.1016/j.ejphar.2021.173995
European Journal of Pharmacology; Aizawa N, Fujimori Y et. al.

Mar 6th, 2021 - Transient receptor potential melastatin 8 (TRPM8) channels may contribute to the pathophysiological bladder afferent hyperactivity, thus a TRPM8 antagonist would be a promising therapeutic target for the bladder hypersensitive disorders including ...

see more →

Guidelines  4 results

Design and Methodological Considerations of the Centers for Disease Control and Prevent...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5201100
The Journal of Urology; Routh JC, Cheng EY et. al.

Oct 24th, 2016 - Care of children with spina bifida has significantly advanced in the last half century, resulting in gains in longevity and quality of life for affected children and caregivers. Bladder dysfunction is the norm in patients with spina bifida and may...

Neurogenic lower urinary tract dysfunction: Clinical management recommendations of the ...
https://doi.org/10.1002/nau.23027
Neurourology and Urodynamics; Drake MJ, Apostolidis A et. al.

May 13th, 2016 - Evidence-based guidelines for the management of neurological disease and lower urinary tract dysfunction have been produced by the International Consultations on Incontinence (ICI). These are comprehensive guidelines, and were developed to have wo...

International Children's Continence Society's recommendations for initial diagnostic ev...
https://doi.org/10.1002/nau.22247
Neurourology and Urodynamics; Bauer SB, Austin PF et. al.

Apr 25th, 2012 - The objective of this ICCS standardization document is to report the initial diagnostic evaluation and subsequent work-up of children with neuropathic bladder dysfunction. Due to a paucity of level I or level II, "levels of evidence" publications,...

Clinical guideline for male lower urinary tract symptoms.
https://doi.org/10.1111/j.1442-2042.2009.02369.x
International Journal of Urology : Official Journal of Th... Homma Y, Araki I et. al.

Oct 8th, 2009 - This article is a shortened version of the clinical guideline for lower urinary tract symptoms (LUTS), which has been developed in Japan for symptomatic men aged 50 years and over irrespective of presumed diagnoses. The guideline was formed on the...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  1,489 results

ACTG2 Visceral Myopathy - GeneReviews® - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/n/gene/actg2-dis/

May 5th, 2021 - ACTG2 visceral myopathy is a disorder of smooth muscle dysfunction of the bladder and gastrointestinal system with phenotypic spectrum that ranges from mild to severe. Bladder involvement can range from neonatal megacystis and megaureter (with its...

Is coronavirus disease 2019 associated with indicators of long-term bladder dysfunction?
https://doi.org/10.1002/nau.24682
Neurourology and Urodynamics; Welk B, Richard L et. al.

May 4th, 2021 - Early reports have suggested that coronavirus disease 2019 (COVID-19) can present with significant urinary frequency and nocturia, and that these symptoms correlate with markers of inflammation in the urine. We evaluated surrogate markers of chron...

Physical activity effects on bladder dysfunction in an obese and insulin-resistant muri...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077148
Physiological Reports; de Oliveira AM, Fonseca FMF et. al.

Apr 27th, 2021 - To investigate the role of physical activity in functional and molecular bladder alterations in an obese and insulin-resistant murine model. Wistar rats were randomized into 1. physical activity and standard diet; 2. physical activity and high-fat...

FDA Approves Myrbetriq to Treat Pediatric NDO
https://www.medscape.com/viewarticle/948305

Mar 28th, 2021 - The US Food and Drug Administration (FDA) has expanded the indication for Mirabegron (Myrbetriq/Myrbetriq Granules) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurologic impairment, in children aged 3 years a...

Suspected cauda equina syndrome: no reduction in investigation, referral and treatment ...
https://doi.org/10.1308/rcsann.2021.0011
Annals of the Royal College of Surgeons of England; Woodfield J, Brennan PM et. al.

Mar 8th, 2021 - Compression of the cauda equina can lead to bladder, bowel and sexual dysfunction with lower limb pain, numbness and weakness. Urgent surgical decompression aims to prevent progressive neurological deficit. Symptoms of cauda equina syndrome (CES),...

see more →

News  21 results

FDA Approves Myrbetriq to Treat Pediatric NDO
https://www.medscape.com/viewarticle/948305

Mar 28th, 2021 - The US Food and Drug Administration (FDA) has expanded the indication for Mirabegron (Myrbetriq/Myrbetriq Granules) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurologic impairment, in children aged 3 years a...

Cannabinoids Mildly Effective for Multiple Sclerosis Symptoms
https://www.medscape.com/viewarticle/903571

Oct 16th, 2018 - Medicinal cannabinoids are helpful for treatment of spasticity, pain, and bladder dysfunction for patients with multiple sclerosis (MS), although their efficacy is "limited," new research suggests. Mari Carmen Torres-Moreno, PhD, and colleagues at...

Fast Five Quiz: How Much Do You Know About Mechanical Low Back Pain?
https://reference.medscape.com/viewarticle/866828_4

Dec 14th, 2017 - Any history of new-onset bowel or bladder dysfunction (eg, urinary hesitancy, overflow incontinence) with back pain is suggestive of cauda equina syndrome. This is particularly true if other, new neurologic deficits are also present. For more on t...

Are Bladder Dysfunction and Falls Related in MS?
https://www.mdedge.com/neurology/msresourcecenter/article/148118/multiple-sclerosis/are-bladder-dysfunction-and-falls

Sep 27th, 2017 - Urinary urgency with incontinence is associated with recurrent falls in people with relapsing-remitting multiple sclerosis (MS) with mild to moderate disability, according to data published in the July–August issue of International Journal of MS C.

FDA Approves First Treatment for a Form of Bladder Dysfunction in Pediatric Patients as Young as 2 Years of Age
http://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-form-bladder-dysfunction-pediatric-patients-young-2-years-age

For Immediate Release: May 26, 2020 The U.S. Food and Drug Administration today granted approval to VESIcare LS (solifenacin succinate) oral suspension, a liquid taken by mouth, for the treatment of neurogenic detrusor overactivity (NDO), a form o...

see more →